Metabolic profiling of a myalgic encephalomyelitis/chronic fatigue syndrome discovery cohort reveals disturbances in fatty acid and lipid metabolism. — CFSMEATLAS
Metabolic profiling of a myalgic encephalomyelitis/chronic fatigue syndrome discovery cohort reveals disturbances in fatty acid and lipid metabolism.
Germain, Arnaud, Ruppert, David, Levine, Susan M et al. · Molecular bioSystems · 2017 · DOI
Quick Summary
This study examined the chemicals in the blood of 17 ME/CFS patients and compared them to 15 healthy people. Researchers found 74 different chemicals at abnormal levels in ME/CFS patients, with 35 showing significant differences. Many of these chemicals are important for producing energy in the body, which could help explain why ME/CFS patients feel so exhausted.
Why It Matters
This research provides potential metabolic biomarkers that could help diagnose ME/CFS objectively, addressing a major gap since no current biological tests confirm the disease. Understanding which metabolic pathways are disrupted offers insights into why patients experience profound fatigue and could guide development of targeted treatments.
Observed Findings
74 differentially accumulating metabolites identified (P < 0.05); 35 metabolites remained significantly altered after multiple testing correction (Q < 0.15)
Key energy-related compounds were reduced or depleted in ME/CFS patients, including glucose, oxaloacetate, ADP, and ATP
Disruptions in fatty acid metabolism pathways, particularly taurine metabolism, glycerophospholipid metabolism, and primary bile acid metabolism
Abnormalities in purine and pyrimidine metabolism (nucleotide building blocks for DNA/RNA and energy production)
Alterations in multiple amino acid metabolic pathways
Inferred Conclusions
Metabolic profiling reveals disturbances in multiple interconnected pathways involved in energy production and fatty acid metabolism in ME/CFS patients
Energy-related metabolite abnormalities may provide a biochemical basis for the characteristic lack of energy in ME/CFS
Plasma metabolic signatures could represent a prospective biomarker approach for ME/CFS diagnosis and disease understanding
The complex metabolic disturbances suggest ME/CFS involves multi-system biochemical dysfunction rather than single-pathway disease
Remaining Questions
Do these metabolic abnormalities persist over time, or do they fluctuate with symptom severity and disease activity?
What This Study Does Not Prove
This study does not prove that metabolic abnormalities cause ME/CFS—it only shows they are associated with the disease. The small sample size and lack of independent replication mean these findings must be confirmed in larger studies before use in clinical diagnosis. The cross-sectional design cannot establish whether metabolic changes occur before, during, or after disease onset.